Education, EUGLOH, Research
SPOC MIRACIP: Management of immunorelated complication of cancer immunotherapy
… SPOC MIRACIP: Management of immunorelated complication of cancer immunotherapy SPOC MIRACIP: … cancer treatment. Although ICIs are the most promising drugs, they are associated with side effects in around 70% of treated patients, such called … are the most promising drugs, they are associated with side effects in around 70% of treated patients, such called …
Published on: